Home Executive-Insights CCO RoslinCT Appoints Dr. Jessica ...

RoslinCT Appoints Dr. Jessica Carmen as Chief Commercial Officer

CCO

Business Honor
04 November, 2024

Dr. Jessica Carmen joins RoslinCT as CCO to accelerate business growth in cell therapy manufacturing.

Cell therapy manufacturing leader RoslinCT has appointed Dr. Jessica Carmen as its new Chief Commercial Officer (CCO). With over 20 years of experience in business development, licensing, and marketing in the cell and gene therapy industry, Dr. Carmen brings vast experience to the company. She comes from Kincell Bio, where she served as Vice President of Business Development.

Dr. Carmen will report to the management of RoslinCT and coordinate and oversee all commercial activities, with an emphasis on marketing the company's technical capabilities and driving business development while strengthening customer relationships. She will play a key part in the integrated global leadership team as she collaborates with operations in major life sciences hubs, such as Boston and Edinburgh.

Elated with Dr Carmen's appointment as Executive Vice President of Business Development, the company's Executive Chairman, and Geoffrey Hamilton-Fairley, stated the industry network, as well as her deep knowledge of the technical aspects of manufacturing cell-based therapies, was critical. "Jessica's expertise will be crucial in attracting more cell therapy developers to our sites and further enhancing the support we provide for innovative products currently in production," said Hamilton-Fairley.

Reflecting on her new role, Dr Carmen expressed excitement at joining the RoslinCT mission to stay ahead of the curve when it comes to cell therapy manufacturing. "RoslinCT is a trusted leader in clinical and commercial cell therapy manufacturing, and I look forward to driving the company's long-term growth and supporting the developers and patients who benefit from these groundbreaking therapies," she said.

The addition of Dr. Carmen underscores RoslinCT's commitment to expanding its capabilities in the rapidly growing field of cell and gene therapy, enhancing its leadership in delivering high-quality manufacturing services for the industry.